Kumar Naveen, Choudhary Narendra S
Hepatology and Gastroenterology, Narayana Hospital Delhi, India.
Hepatology, Medanta The Medicity, Gurgaon, Delhi (NCR), India.
J Clin Exp Hepatol. 2024 Mar-Apr;14(2):101287. doi: 10.1016/j.jceh.2023.09.008. Epub 2023 Sep 23.
Hepatitis B and C are common causes of end-stage liver disease and etiologies of liver transplantation. It is important to prevent recurrence in cases of hepatitis B. Nucleos(t)ide analogs are the mainstay of HBV treatment before (in patients with decompensated cirrhosis) and after liver transplantation. After the introduction of direct-acting antivirals, the treatment of HCV has become considerably easy. In patients with advanced HCV-related cirrhosis, it is better to do transplantation first and treat them after liver transplantation. The sustained virological response rates have improved from 8 to 50% in the interferon era to 90% in the direct-acting antivirals era. In the current review, we discuss the treatment of HBV and HCV before and after liver transplantation.
乙型肝炎和丙型肝炎是终末期肝病的常见病因及肝移植的病因。预防乙型肝炎复发很重要。核苷(酸)类似物是肝移植前(失代偿性肝硬化患者)和肝移植后乙肝治疗的主要药物。直接抗病毒药物问世后,丙型肝炎的治疗变得相当容易。对于晚期丙型肝炎相关肝硬化患者,最好先进行移植,然后在肝移植后进行治疗。持续病毒学应答率已从干扰素时代的8%至50%提高到直接抗病毒药物时代的90%。在本综述中,我们讨论肝移植前后乙肝和丙肝的治疗。